Twitter Beğeni Hilesi

Part 2 melanoma with the expert Dr. Mike Atkins this week discussing: The Aha moment when he saw IO changing the landscape 🌟 When to use LAG3 combo DREAMseq IO vs BRAF for which he was 1st author 🌟 Oligometastatic dx Uveal / mucosal melanoma Career tips #meded

Have spent a lot of time thinking about the #CLEAR & #KN426 biomarker presentations at #ASCO24 by Toni Choueiri, MD & Brian Rini, MD. Huge efforts & grateful that investment was made in this work. Could the differences observed in the association of immune signatures with outcome lend

We released an update on our most listened episode topic - AML - w/ a special guest Dr. Catherine Lai from U Penn! In Part 1 we discuss the presentation, diagnostic work-up, and updates on the classification of AMLs, as well as tips to remember them 🩸

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Please consider enrolling at your institution. Matt Galsky and I discuss the importance of the @AllianceNCTN A032103 MODERN study, a ctDNA 🧬 informed approach to adjuvant bladder cancer therapy. MRD+ patients get PD1 or PD1/LAG3 Bladder Cancer Advocacy Network Jonathan Rosenberg MD Andrea Apolo, M.D.

Asked to predict the future of advanced bladder cancer post neoadjuvant therapy #GUARDSymposium2024 Enrique Grande points out my tack record of predicting the future is not that great,l.

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro prnewswire.com/news-releases/…

In this Q&A, Karine Tawagi MD of UI Health and Samantha Armstrong of IU Simon Comprehensive Cancer Center, both active members of the Big Ten CRC and Hoosier Cancer, share how they launched their TwoOncDocs podcast. Read more: cancer.uillinois.edu/two-onc-docs-w…

Phenomenal day at Bladder Cancer Advocacy Network #BCANTT24 with many friends/colleagues! Impressive performance by DrTylerStewart & his band! Shilpa Gupta Eugene Pietzak Omar Mian Shailender Bhatia, MD Dr. Bishoy M. Faltas Parminder singh Karine Tawagi MD Alan Tan Vadim Koshkin MD Sarah P. Psutka MD MS Thomas Flaig Stephanie Chisolm, PhD

Opportunities for 🚬 cessation by Dr. Bjurlin at #BCANthinktank Bladder Cancer Advocacy Network 🟧 only ~20% of pts knew smoking RF for BCa 🟨 1/3 of all visits with urologists are for tobacco-related disease 🟧 active smokers 3x more likely to die of BCa then former smokers

2015 vs 2024 National Comprehensive Cancer Network (NCCN) guidelines for Advanced Bladder Cancer Remarkable how far we have come in 10 years as we have improved our treatment options for better patient outcomes in BCa 🧡Bladder Cancer Advocacy Network #BCANTT24

Expert panel #BCANTT24 on the future of IO in BCa: 🟨 key ongoing trials w/ recent NIAGARA read-out 🟧 lack biomarkers of response & resistance, PDL1 is not it  ➡️ need de-escalation as many pt advocates expressed this meeting  ❓inc consolidation for CR in mUC, IO post IO

So excited to chat with rising superstar Karine Tawagi MD about her 1st Bladder Cancer Advocacy Network #BCANTT24 experience! Great to have dedicated colleagues in fight vs #bladdercancer World Bladder Cancer Patient Coalition Stephanie Chisolm, PhD Uromigos Alan Tan Shilpa Gupta Ashish M. Kamat, MD, MBBS thanks for video DrTylerStewart

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer. Toni Choueiri, MD Brian Rini, MD Laurence Albiges ⬆️ RR, PFS, QOL but no OS. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited

We've had no data on real-world EV+P use for mUC, until now. In European Urology we show rapid dissemination of EV+P in practice. As of 3/31/24, <4 mo after U.S. FDA full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). authors.elsevier.com/a/1jeFg14kplyy…

T -3 weeks til #ESMO24! Presidential plenaries are online — ⭐️ 9/14 silke gillessen #PEACE3 radium-enza vs enza in #prostatecancer ⭐️ 9/15 Tom Powles #NIAGARA durva-chemo in #bladdercancer, discussed by Petros Grivas! See you in Barcelona! #ESMOAmbassadors ESMO - Eur. Oncology OncoAlert

We just released a new episode w/ Dr. Janet Abrahm from Dana-Farber, a national leader in palliative care, impt for any specialty! We cover: 🌟how to explain pall care to pts 🌟pain & anti-emetic management 🌟non-pharmacologic strategies 🌟innovations podcasts.apple.com/us/podcast/two…

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24